IGMS (IGM Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IGMS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-08-15 | Jeremy Green | 10%+ Owner | D | — | — |
| 2025-08-14 | Elizabeth H.Z. Thompson | Director | D | — | — |
| 2025-08-14 | Julie Hambleton | Director | D | — | — |
| 2025-08-14 | William Strohl | Director | D | — | — |
| 2025-08-14 | Mary Beth Harler | Chief Executive Officer | D | — | — |
| 2025-08-14 | Michael Stewart Lee | Director | D | — | — |
| 2025-08-14 | Topsoe Holding A/S | 10%+ Owner | D | — | — |
| 2025-08-14 | Jakob Haldor Topsoe | Director | D | — | — |
| 2025-08-14 | M KATHLEEN BEHRENS | Director | D | — | — |
| 2025-08-14 | Christina Teng Topsoe | Director | D | — | — |
| 2025-07-25 | Misbah Tahir | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-07-25 | Lisa Lynn Decker | CHIEF BUSINESS OFFICER | Sell | — | — |
| 2025-07-25 | Mary Beth Harler | Chief Executive Officer | Sell | — | — |
| 2025-07-02 | Michael Stewart Lee | Director | A | — | — |
| 2025-07-02 | Elizabeth H.Z. Thompson | Director | A | — | — |
| 2025-07-02 | Redmile Group, LLC | Director | A | — | — |
| 2025-07-02 | JULIAN BAKER | Director | A | — | — |
| 2025-07-02 | Christina Teng Topsoe | Director | A | — | — |
| 2025-07-02 | Jakob Haldor Topsoe | Director | A | — | — |
| 2025-07-02 | M KATHLEEN BEHRENS | Director | A | — | — |
| 2025-06-20 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sell | — | — |
| 2025-06-20 | Lisa Lynn Decker | CHIEF BUSINESS OFFICER | Sell | — | — |
| 2025-06-20 | Mary Beth Harler | Chief Executive Officer | Sell | — | — |
| 2025-06-20 | Misbah Tahir | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-05-16 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sell | — | — |
| 2025-04-02 | Jeremy Green | Director | A | — | — |
| 2025-04-02 | Christina Teng Topsoe | Director | A | — | — |
| 2025-04-02 | Jakob Haldor Topsoe | Director | A | — | — |
| 2025-04-02 | JULIAN BAKER | Director | A | — | — |
| 2025-04-02 | M KATHLEEN BEHRENS | Director | A | — | — |
| 2025-04-02 | Michael Stewart Lee | Director | A | — | — |
| 2025-04-02 | Elizabeth H.Z. Thompson | Director | A | — | — |
| 2025-03-18 | Mary Beth Harler | Chief Executive Officer | Sell | — | — |
| 2025-03-18 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sell | — | — |
| 2025-03-18 | Misbah Tahir | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-03-18 | Lisa Lynn Decker | CHIEF BUSINESS OFFICER | Sell | — | — |
| 2025-01-17 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sell | — | — |
| 2025-01-03 | M KATHLEEN BEHRENS | Director | A | — | — |
| 2025-01-03 | Jakob Haldor Topsoe | Director | A | — | — |
| 2025-01-03 | Christina Teng Topsoe | Director | A | — | — |
| 2025-01-03 | Elizabeth H.Z. Thompson | Director | A | — | — |
| 2025-01-03 | 667, L.P. | Director | A | — | — |
| 2025-01-02 | Michael Stewart Lee | Director | A | — | — |
| 2025-01-02 | Jeremy Green | 10%+ Owner | A | — | — |
| 2024-12-18 | Lisa Lynn Decker | CHIEF BUSINESS OFFICER | Sell | — | — |
| 2024-12-18 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | Sell | — | — |
| 2024-12-18 | Misbah Tahir | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2024-12-18 | Mary Beth Harler | Chief Executive Officer | Sell | — | — |
| 2024-11-20 | Misbah Tahir | CHIEF FINANCIAL OFFICER | A | — | — |
| 2024-11-12 | Steven Weber | PRINCIPAL ACCOUNTING OFFICER | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 3,759,462 | — |
| — | Director | 3,123,770 | — |
| — | Director | 2,964,843 | — |
| — | Director | 2,883,204 | — |
| — | CEO AND PRESIDENT | 446,842 | — |
| — | Director | 357,048 | — |
| — | Director | 355,142 | — |
| — | Director | 274,006 | — |
| — | CHIEF SCIENTIFIC OFFICER | 246,987 | — |
| — | CHIEF FINANCIAL OFFICER | 170,061 | — |
| — | CHIEF MEDICAL OFFICER | 154,331 | — |
| — | Chief Medical Officer | 117,461 | — |
| — | CHIEF BUSINESS OFFICER | 68,169 | — |
| — | Director | 49,121 | — |
| — | Chief Commercial Officer | 39,642 | — |
| — | PRINCIPAL ACCOUNTING OFFICER | 26,530 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IGMS quote page; the site-wide leaderboard is on the insider transactions hub.